演讲者

PLENARY KEYNOTES

  • K. Dane Wittrup, PhD, C.P. Dubbs Professor, Chemical Engineering and Biological Engineering; Associate Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)
  • 2018 YOUNG SCIENTIST KEYNOTE
    Kipp Weiskopf, MD, PhD, Resident Physician, Internal Medicine, Brigham and Women’s Hospital

Engineering Stream
DISPLAY OF ANTIBODIES

  • Andrew M. Bradbury, PhD, MB BS, CSO, Specifica, Inc.
  • Frederic D. Bushman, PhD, Chair and Professor, Microbiology, University of Pennsylvania
  • Bryce Chackerian, PhD, Professor, Molecular Genetics and Microbiology, University of New Mexico School of Medicine
  • Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular
  • Stefan Ewert, PhD, Senior Investigator, NIBR Biologics Center, Novartis Pharma AG
  • Benjamin Hackel, PhD, Associate Professor, Chemical Engineering and Materials Science, University of Minnesota
  • Guy Hermans, PhD, CSO, Isogenica Ltd.
  • Mitchell Ho, PhD, Senior Investigator, National Cancer Institute, NIH
  • Joseph Jardine, PhD, Head, Antibody Discovery, Institute for Protein Innovation
  • David R. Liu, PhD, Richard Merkin Professor, Director, Merkin Institute of Transformative Technologies in Healthcare, Broad Institute Core Institute Member, Vice-Chair, Faculty, Director of the Chemical Biology and Therapeutic Sciences Program, Howard Hughes Medical Institute Investigator, Professor, Chemistry and Chemical Biology, Harvard University
  • Chuanbin Mao, PhD, Professor, Chemistry and Biochemistry, University of Oklahoma
  • Jennifer Maynard, PhD, Associate Professor, Chemical Engineering, University of Texas at Austin
  • James M. Olson, MD, PhD, Sarah Hughes Chair for Pediatric Oncology; Member, Fred Hutchinson Cancer Research Center; Attending Physician, Seattle Children’s Hospital; Professor of Pediatrics, University of Washington
  • Timothy Palzkill, PhD, Professor, Chair, Pharmacology and Chemical Biology, Baylor College of Medicine
  • Balaji M. Rao, PhD, Associate Professor, Chemical and Biomolecular Engineering, North Carolina State University
  • Aaron Sato, PhD, CSO, Antibody Center, LakePharma
  • Leila Sevigny, PhD, Senior Scientist, Sanofi Genzyme
  • Ernest Smith, CSO & Senior Vice President, Research, Vaccinex, Inc.
  • Greg M. Thurber, PhD, Assistant Professor, Chemical Engineering and Biomedical Engineering, University of Michigan
  • Benjamin Umlauf, PhD, Post-Doctoral Fellow, Chemical and Biological Engineering Department, University of Wisconsin

 

ENGEINEERING ANTIBODIES

  • Gregory Carven, PhD, Vice President, Antibody Discovery & Protein Sciences, Scholar Rock
  • Joel Cohen-Solal, PhD, Senior Research Scientist, Global Protein Sciences, AbbVie Bioresearch Center
  • Caroline Colley, PhD, Associate Director, Antibody Discovery and Protein Engineering, MedImmune, United Kingdom
  • Bruno Correia, PhD, Professor, Protein Design and Immunoengineering, EPFL Zurich, Switzerland
  • Pierre-Alain Girod, PhD, CSO, Selexis SA
  • David S. Johnson, PhD, CEO, GigaGen
  • JT Koerber, PhD, Scientist, Antibody Engineering, Genentech
  • Tim Larson, PhD, Marketing Specialist I, Marketing, Takara Bio USA
  • Chang-Han Lee, PhD, Postdoctoral Researcher, Georgiou Lab, The University of Texas at Austin
  • Greg Lazar, PhD, Director, Antibody Engineering, Genentech
  • Jonas Schaefer, PhD, Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich, Switzerland
  • Eva-Maria Strauch, PhD, Research Assistant Professor, Biochemistry, University of Washington
  • Lioudmila Tchistiakova, PhD, Senior Director, Global Biotherapeutic Technologies, Pfizer
  • Danlin Yang, PhD, Scientist, Biotherapeutics Discovery, Boehringer Ingelheim
  • Andy Yeung, PhD, Associate Research Fellow, Rinat, Oncology R&D, Pfizer, Inc.

ENGINEERING BISPECIFIC ANTIBODIES

  • Edward A. Berger, PhD, Chief, Molecular Structure Section, Laboratory of Viral Diseases, NIAID, National Institutes of Health
  • Stanislas Blein, PhD, Senior Director, Head Antibody Engineering, Biologics Research, Glenmark Pharmaceuticals S.A.
  • Ulrich Brinkmann, PhD, Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Munich (RICM), Penzberg, Germany
  • Yvonne Y. Chen, PhD, Assistant Professor, Chemical and Biomolecular Engineering, University of California, Los Angeles
  • Mark Cobbold, MD, PhD, Cellular Immunotherapy Program, Center for Cancer Immunology, Massachusetts General Hospital; Member of the Faculty of Medicine, Harvard Medical School
  • John de Kruif, PhD, CTO, Merus NV
  • Nicolas Fischer, PhD, Head of Research, Novimmune
  • Yanwen Fu, PhD, Director, Antibody Technology and Chemical Biology, Sorrento Therapeutics
  • Stephen Gottschalk, MD, Chair, Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Research Hospital
  • Steven M. Larson, MD, FACNM, FACR, Donna and Benjamin M. Rosen Chair, Attending Molecular Imaging and Therapy Service, Radiology; Member and Lab Head, Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute; Professor, Radiology, Weill Cornell University Medical Center, Radioimmunotherapy and Theranostics, Ludwig Center
  • Jeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Hematology, Oncology and Transplantation, University of Minnesota
  • Amarendra Pegu, PhD, Staff Scientist, Laboratory of Virology, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH
  • Mitsuo Umetsu, PhD, Professor, Biomolecular Engineering, Graduate School of Engineering, Tohoku University
  • Thomas J. Van Blarcom, PhD, Associate Research Fellow, Oncology Research and Development, Pfizer, Inc., Rinat Laboratories
  • Maria Wendt, PhD, Head, Science, Biologics, Genedata
  • Chengbin Wu, PhD, CEO, EpimAb Biotherapeutics

Oncology Stream
ANTIBODIES FOR CANCER THERAPY

  • Ezio Bonvini, MD, Senior Vice President, Research & CSO, MacroGenics, Inc.
  • Paul B. Chapman, MD, Physician & Scientist, Memorial Sloan Kettering Cancer Center
  • Nai-Kong V. Cheung, MD, PhD, Head, Neuroblastoma Program; Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center
  • Bradley St. Croix, PhD, Senior Associate Scientist, Head, Tumor Angiogenesis Unit, Mouse Cancer Genetics Program, National Cancer Institute
  • Achim Doerner, PhD, Principal Scientist, Protein Engineering and Antibody Technologies, Merck KGaA Darmstadt, Germany
  • Gianpietro Dotti, MD, Lineberger Comprehensive Cancer Center Member, Professor, Microbiology and Immunology; Director, Lineberger Immunotherapy Program, University of North Carolina School of Medicine
  • Tim F. Greten, MD, Senior Investigator, GI Maligancy Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute
  • Mitchell Ho, PhD, Senior Investigator, National Cancer Institute, NIH
  • Patrick Mehlen, PhD, CEO Netris Pharma, Centre Leon Berard
  • Horacio G. Nastri, PhD, Senior Director, Antibody Biotherapeutics, Incyte Corporation
  • Junichi Nezu, PhD, Senior Specialist, Project & Lifecycle Management Unit, Chugai Pharmaceutical, Co., Ltd.
  • Patrick Ott, MD, PhD, Clinical Director, Melanoma Center; Clinical Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School
  • Ira H. Pastan, MD, Scientist, NIH NCI
  • Soldano Ferrone, MD, PhD, Surgical Oncology, Surgery, Massachusetts General Hospital
  • Kelli Ryan, PhD, Senior Scientist, Oncology Department, MedImmune
  • William R. Strohl, PhD, Owner and President, BiStro Biotech Consulting, LLC
  • Mark Throsby, PhD, CSO, Merus NV
  • Jennifer Wargo, MD, Melanoma Research, MD Anderson Cancer Center
  • Louis Weiner, MD, Professor, Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
  • Mingjie Xie, CEO, Rapid Novor, Inc.

ADVANCING BISPECIFIC ANTIBODIES AND COMBINATION THERAPY TO THE CLINIC

  • Julian Andreev, PhD, Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals
  • Tara Arvedson, PhD, Director, Oncology Research, Amgen, Inc.
  • Carl Uli Bialucha, PhD, Oncology Biotherapeutics, Novartis Institutes for BioMedical Research, Inc.
  • Adrian Bot, MD, PhD, CSO, Kite Pharma, Inc.
  • Chien-Hsing Ken Chang, PhD, Vice President, Research & Development, Immunomedics, Inc.
  • Raphael Clynes, MD, PhD, Vice President, Translational Biology, Xencor, Inc.
  • Frank Comer, PhD, Scientist, MedImmune
  • Rakesh Dixit, PhD, DABT, Vice President, R&D, Global Head, Biologics Safety Assessment, Translational Sciences, MedImmune
  • David D. Ho, MD, Aaron Diamond AIDS Research Center, The Rockefeller University
  • Dirk Hose, PhD, Priv.-Doz. Dr. med. Dr. biol. hom., Head, Multiple Myeloma Research Laboratory, Universitaetsklinikum Heidelberg, Medizinische Klinik V
  • Ross La Motte-Mohs, PhD, Scientist III, Cell Biology and Immunology, MacroGenics, Inc.
  • G. Jonah Rainey, PhD, Executive Director, Head of Antibody Research, MabVax Therapeutics Holdings, Inc.
  • Leonard Seymour, PhD, Professor, Gene Therapy, Oncology, University of Oxford
  • Jacintha Shenton, PhD, Scientific Director, Biologics Toxicology, Janssen BioTherapeutics, Janssen R&D
  • Michael Tesar, PhD, Research Program Head, Research and Development, Affimed GmbH
  • Bob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics
  • Zhulun Wang, PhD, Executive Director, Biologics Department, Amgen

CLINICAL PROGRESS OF ANTIBODY-DRUG CONJUGATES

  • Adnan Abu-Yousif, PhD, Senior Scientist II, Discovery, Takeda
  • Donald A. Bergstrom, MD, PhD, CMO, Mersana Therapeutics
  • Anna Berkenblit, MD, MMSc, Vice President, CMO, ImmunoGen
  • Mahendra Deonarain, PhD, CEO & CSO, Antikor Biopharma Ltd.
  • David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
  • Trevor J. Hallam, PhD, CSO, Sutro Biopharma
  • Jay Harper, PhD, Senior Scientist, Oncology Research, MedImmune
  • Philip Howard, PhD, CSO, Spirogen; Senior Fellow, MedImmune
  • Gail Lewis Phillips, MSc, Senior Scientist, Translational Oncology, Genentech, Inc.
  • David (Shih-Yao) Lin, MD, PhD, CMO, AbGenomics, Inc.
  • Ed Reilly, PhD, Senior Research Fellow, Project Director, Oncology Discovery, AbbVie
  • Renu Singh Dhanikula, PhD, Senior Research Investigator, MAP, Bristol-Myers Squibb Company
  • Pamela Trail, Independent Consultant and Former Vice President, Oncology, Regeneron
  • Alessandra Micaela Villa, PhD, Head, Phage Display Technologies, Philochem AG
  • Jeff Wallin, PhD, Senior Director and Head, Biomarkers & Diagnostics, Seattle Genetics
  • William C. Zamboni, PharmD, PhD, Associate Professor and Director, Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Laboratory, UNC Lineberger Comprehensive Cancer Center

Immunotherapy Stream
IMPROVING IMMUNOTHERAPY EFFICACY AND SAFETY

  • Andrew Allen, MD, PhD, President & CEO, Gritstone Oncology, Inc.
  • Carlo Boutton, PhD, Director Technology & Information Management, Ablynx
  • Daniel Christ, PhD, Associate Professor, Director Centre for Targeted Therapy, Garvan Institute of Medical Research
  • Robert Hofmeister, PhD, CSO, Executive Leadership Team, TCR2 Therapeutics, Inc.
  • Alex Kelly, US Business Development Manager, Retrogenix
  • Saad J. Kenderian, Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine
  • Kathleen McGinness, PhD, Senior Director, Platform Technologies, Unum Therapeutics
  • Douglas Jolly, PhD, Executive Vice President, Research & Pharmaceutical Development, Research & Pharmaceutical Development, Tocagen Inc.
  • Maksim Mamonkin, PhD, Instructor, Center for Cell and Gene Therapy, Baylor College of Medicine
  • Daniel J. Powell Jr., PhD, Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania
  • Laszlo Radvanyi, PhD, Senior Vice President, Senior Scientific Advisor - Immunology, Immuno-Oncology, EMD Serono R&D Institute
  • Robert R. Salzler, PhD, Scientist, Bioanalytical & Biomarker Technologies, Regeneron Pharmaceuticals, Inc.
  • Steven Shamah, PhD, SVP, Head of Research, Obsidian
  • Naomi De Silva, PhD, Associate Director, Preclinical and Translational Science, Clinical, Sillajen Biotherapeutics, Inc.
  • Steven J. Swanson, PhD, Senior Vice President, Research, ImmunoCellular Therapeutics, Ltd.
  • Carston R. Wagner, PhD, Professor, Department of Medicinal Chemistry, University of Minnesota, and CSO, Tychon Bioscience, LLC
  • Claudia Wagner, PhD, Associate Director, TCR Discovery & Validation, Immatics

CAR Ts, TCRs AND TILs

  • J. Henri Bayle, PhD, Director of Molecular Biology, Research and Development, Bellicum Pharmaceuticals
  • Mark Bonyhadi, PhD, Head, Research, Juno Therapeutics
  • Adrian Bot, MD, PhD., Vice President, Translational Sciences, Kite, a Gilead Company
  • Mark Dudley, PhD, Senior Vice President, Bioprocessing & Development CMC, Technical Operations, Adaptimmune
  • Maria Fardis, PhD, CEO, Iovance
  • David Gilham, PhD, Vice President, Research, Celyad
  • Collin Hauskins, Research Scientist, Protein Sciences, Juno Therapeutics
  • Hans Klingemann, MD, PhD, Vice President, Research & Development, NantKwest, Inc.
  • Jeffrey S. Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota University of Minnesota
  • Molly Perkins, DPhil, Associate Director, Immunotherapy, bluebird bio
  • Paul Rennert, PhD, President & CSO, Aleta Biotherapeutics Inc
  • Michel Sadelain, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
  • Andrew Sewell, PhD, Professor, Division of Infection and Immunity, Cardiff University School of Medicine
  • Bob Valamehr, PhD, Vice President, Cancer Immunotherapy, Fate Therapeutics

AGONIST IMMUNOTHERAPY TARGETS

  • Adam J. Adler, PhD, Professor, Immunology, University of Connecticut
  • Casey Ager, Graduate Research Assistant, Department of Immunology, University of Texas MD Anderson Cancer Center
  • Saso Cemerski, PhD, Principal Scientist, Merck Research Labs
  • Deborah H. Charych, PhD, Executive Director, Nektar Therapeutics
  • Adi Diab, PhD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
  • Peter Ellmark, PhD, Principal Scientist, R&D, Alligator Bioscience
  • Denise L. Faustman, MD, PhD, Director of Immunobiology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
  • Claudia Ferrara, PhD, Principal Scientist, Large Molecule Research, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich
  • Oliver Hill, PhD, Vice President, Molecular Biology, Apogenix
  • Debbie Law, DPhil, CSO, Jounce Therapeutics
  • Patrick Mayes, PhD, Executive Director, Head, IO Antibody Research, Incyte
  • Dafne Muller, PhD., Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart
  • Taylor Schreiber, PhD, CSO, Research & Development, Shattuck Labs, Inc.
  • Harpreet Singh, President & CEO, Immatics US
  • Robert B. Stein, MD, PhD, Senior Advisor, R&D, Agenus, Inc.
  • Michael Yellin, MD, Vice President, Clinical Science, Celldex

Expression Stream
DIFFICULT TO EXPRESS PROTEINS

  • Randal Bass, PhD, Vice President, Just Biotech
  • Matthew A. Coleman, PhD, Senior Scientist, Lawrence Livermore National Laboratory
  • Hussain Dahodwala, PhD, Visiting Scientist, Vaccine Production Program, Vaccine Research Center, NIH
  • Martin Gamer, PhD, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Haruki Hasegawa, PhD, Department of Therapeutic Discovery, Amgen
  • Akinori Hishiya, PhD, Principal Scientist, Biology, SOLA BioSciences
  • Azad Kumar, PhD, Viral Pathogenesis Laboratory, NIH/NIAID
  • David Laidlaw, CEO, Kuhner Shaker, Inc.
  • Kerstin Otte, PhD, Professor, Pharmaceutical Biotechnology, Biberach University
  • Harunur Rashid, PhD, Principal Scientist, Ambrx, Inc.
  • Paul Roepe, PhD, Professor, Chemistry, Biochemistry and Mol. Biology, Georgetown University
  • Gargi Roy, MSc, Scientist I, Antibody Discovery and Protein Engineering/Research, MedImmune LLC
  • Joop van den Heuvel, PhD, Department of Structure and Function of Proteins, Helmholtz Centre for Infection Research
  • Ernest Weber, PhD, Senior Scientist, Antibody Lead Discovery, Biologics Research, Bayer AG
  • Yi Xia, MD, Senior Scientific Researcher, Antibody Engineering, Genentech, Inc.
  • Alexei Yeliseev, PhD, Staff Scientist, Group Leader, LMBB, NIH, NIAAA

OPTIMIZING PROTEIN EXPRESSION

  • Nicola Beaucamp, PhD, Head, Process Research, Roche Innovation Center Munich, Pharma Research and Early Development, Roche Diagnostics GmbH
  • Imre Berger, PhD, Professor and Wellcome Trust Senior Investigator, Biochemistry, Biomedical Sciences and BrisSynBio Centre, University of Bristol
  • Jill Carton, PhD, Director, Biologics Discovery, Janssen Biotherapeutics, Janssen R&D
  • Colin Clarke, PhD, Principal Investigator, National Institute for Bioprocessing Research and Training (NIBRT)
  • Jan-Willem de Gier, PhD, Professor, Biochemistry and Biophysics, Stockholm University
  • William Gillette, PhD, Principal Scientist, Deputy Director, Protein Expression Laboratory, Leidos Biomedical Research, Inc.
  • Bernd Voedisch, PhD, Lab Head and Investigator III, NIBR Biologics Center, Novartis Institutes for Biomedical Research
  • Jamey Young, PhD, Associate Professor, Chemical and Biomolecular Engineering, Vanderbilt University
  • Jesse Rinehart, PhD, Associate Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine
  • Robert Roth, PhD, Associate Principal Scientist, Innovative Medicines, Discovery Sciences, AstraZeneca
  • Anne Serdakowski London, PhD, Lab Head, Mid-Scale Mammalian Production, Therapeutic Protein Sciences, Novartis Institutes for Biomedical Research
  • Bernie Sweeney, Senior Group Leader, Mammalian Expression, UCB Pharma
  • Jorg Thommes, PhD, Senior Vice President, Pharmaceutical Sciences & Technology, Visterra, Inc.

PROTEIN EXPRESSION SYSTEM ENGINEERING

  • Abhishek Chatterjee, PhD, Assistant Professor, Chemistry, Boston College
  • Patricia L. Clark, PhD, Rev. John Cardinal O’Hara C.S.C. Professor, Biochemistry, University of Notre Dame
  • Michael Dyson, PhD, CTO, Antibody Engineering, IONTAS, Ltd.
  • Tobias Grosskopf, PhD, Scientist, Cell Culture Research, Roche Diagnostics GmbH
  • Olivier Henry, PhD, Associate Professor, Chemical Engineering, Ecole Polytechnique de Montreal
  • Michael Jewett, PhD, Charles Deering McCormick Professor of Teaching Excellence, and Associate Professor, Chemical and Biological Engineering, Northwestern University
  • Eric Kelsic, PhD, Staff Scientist, Wyss Institute, Harvard University
  • Minseung Kim, MSc, Scientist, Computer Science, UC Davis Genome Center, University of California, Davis
  • Nathan Lewis, Systems Biology & Cell Engineering, University of California, San Diego
  • Colton Lloyd, PhD Candidate, Bioengineering, University of California, San Diego
  • Shahram Misaghi, PhD, Senior Scientist, Early Stage Cell Culture, Genentech, Inc.
  • Dimitris Papamichail, PhD, Assistant Professor, Computer Science, The College of New Jersey
  • Lisa Alexandra Pieper, PhD, Postdoctoral Researcher, Early Stage Bioprocess Development, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Anokha S. Ratnayake, PhD, Principal Scientist, Pfizer Global R&D Groton Labs
  • Lars Stockl, PhD, Senior Director, R&D, Glycotope GmbH

Analytical Stream
CHARACTERIZATION OF BIOTHERAPEUTICS

  • Michael Adamo, Senior Scientist, Bristol-Myers Squibb
  • Eric S. Alonzo, PhD, Scientist, Cellular Analytics, bluebird bio
  • Nathan Brown, PhD, Senior Scientist, AbbVie Bioresearch Center
  • Shan Chung, PhD, Principal Scientist and Group Leader, Genentech
  • Zhimei Du, PhD, Senior Principal Scientist, Merck & Company, Inc.
  • Stacey Helming, PhD, Scientist, Analytical Sciences, Regeneron Pharmaceuticals
  • Vibha Jawa, PhD, Director, Biologics and Vaccine Development, Merck
  • Xin Jiang, Product Manager, iCE, Marketing, ProteinSimple, a Bio-Techne brand
  • Jay Jones, Senior Research Associate, Seattle Genetics
  • Lynn Kamen, PhD, Scientist, Bioanalytical Sciences, Genentech
  • Alex Lazar, PhD, Director, Analytical and Pharmaceutical Sciences, ImmunoGen, Inc.
  • Kelvin Lee, PhD, Professor, Chemical & Biomolecular Engineering, University of Delaware
  • Zhenhong Li, PhD, Senior Director, Analytics, RegenxBio
  • Anthony Mire-Sluis, PhD, Head, Global Quality, AstraZeneca
  • Jennifer F. Nemeth, PhD, SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
  • Da Ren, PhD, Principal Scientist, Amgen
  • Rich Rogers, PhD, Scientist, Just Biotherapeutics
  • Krishnan Sampath, PhD, Senior Director, Analytical and Drug Product Sciences, MacroGenics
  • Zhe Zhang, PhD, Senior Scientist, Integrated Biologics Profiling, Novartis

BIOPHYSICAL ANALYSIS OF BIOTHERAPEUTICS

  • George Bou-Assaf, PhD, Scientist, Technical Development, Biogen
  • Michael Brenowitz, PhD, Professor, Biochemistry and Molecular Pharmacology, Albert Einstein College of Medicine
  • Ralf Joe Carrillo, PhD, Senior Scientist, Physical Chemistry, AbbVie Bioresearch Center
  • John Champagne, Northeast Regional Manager, Wyatt Technology
  • Guodong Chen, PhD, Research Fellow, Bioanalytical and Discovery Analytical Sciences, Bristol-Myers Squibb
  • Mark T. Fisher, PhD, Professor, Biochemistry and Molecular Biology, University of Kansas Medical Center
  • Michael B. Goshe, PhD, Associate Professor, Molecular and Structural Biochemistry, North Carolina State University
  • David Hayes, PhD, Principal Scientist, Boehringer Ingelheim Pharmaceuticals, Inc.
  • Igor Kaltashov, PhD, Associate Professor, Chemistry, University of Massachusetts, Amherst
  • Hubert Kettenberger, PhD, Senior Principal Scientist, Protein Engineering, Roche Innovation Center Munich, Germany
  • Jennifer F. Nemeth, PhD, SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
  • Deniz B. Temel, PhD, Scientist, Amgen
  • Kristopher Truncali, Scientist, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
  • William Weiss, PhD, Principal Research Scientist and Group Leader, Biophysical Characterization, Eli Lilly and Company

PROTEIN AGGREGATION AND STABILITY IN BIOPHARMACEUTICALS

  • Arun Alphonse Ignatius, PhD, Principal Scientist, Pfizer
  • David Brockwell, PhD, Associate Professor, School of Molecular and Cellular Biology, University of Leeds, United Kingdom
  • Didier Clenet, PhD, Research Scientist, Formulation & Stability, Sanofi Pasteur, Canada
  • Tom Crowley, PhD, Principal Scientist, Pharmaceutical R&D, Pfizer, Inc.
  • Zhimei Du, PhD, Head, Cell Line Development, Merck & Company, Inc.
  • Jason Fernandez, Scientist, Protein Pharmaceutical Development, Biogen
  • Raja Ghosh, PhD, Professor, Chemical Engineering, McMaster University, Canada
  • Christoph Grapentin, PhD, Postdoctoral Fellow, Pharmaceutical Development, F. Hoffmann-La Roche Ltd., Switzerland
  • Zhi (Jay) Guo, PhD, Senior Scientist, Global Protein Sciences, AbbVie Bioresearch Center
  • Theodore W. Randolph, PhD, Professor, Chemical & Biological Engineering, University of Colorado, Boulder
  • John Rech, Technology Manager, Particle Testing, Analytical Laboratory, West Pharmaceutical Services
  • Peter Schurtenberger, PhD, Professor, Physical Chemistry, Lund University, Sweden
  • Peter M. Tessier, PhD, Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan
  • Neal Whitaker, PhD, Associate Researcher, Macromolecule and Vaccine Stabilization Center, Pharmaceutical Chemistry, The University of Kansas School of Pharmacy
  • Yingda Xu, PhD, Director, Protein Analytics, Adimab

Immunogenicity & Bioassays Stream
IMMUNOGENICITY CASE STUDIES AND CLINICAL MANAGEMENT

  • Steven Arkin, MD, Executive Director, Clinical Programs, Rare Disease Research Unit, Pfizer Worldwide R&D
  • Adam Cheifetz, MD, Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School
  • Jocelyne Demengeot, PhD, Principal Investigator, Instituto Gulbenkian de Ciencia, Portugal
  • Sandra Garces, MD, PhD, Senior Medical Advisor for Immunogenicity, GPS Medical and Benefit-Risk Management, Eli Lilly and Company
  • Ann Gils, PhD, Professor, Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium
  • George R. Gunn, III, PhD, Head, Immunogenicity and Clinical Immunology, Bioanalysis, Immunogenicity and Biomarkers, In Vitro/In Vivo Translation Platform, GlaxoSmithKline
  • Soumi Gupta, PhD, Director of Immunogenicity, Translational Sciences, BioMarin Pharmaceutical, Inc.
  • Katherine A. High, MD, Co-Founder, President and Head of R&D, Spark Therapeutics
  • M. Benjamin Hock, PhD, Director of Immunogenicity, BioMarin Pharmaceutical Inc.
  • Darshana Jani, Senior Manager, Global Assay Lead, Drug Development, Pfizer
  • Vibha Jawa, PhD, Director, Immunogenicity Strategy for Biologics and Vaccines, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc.
  • Priya Kishnani, MD, C.L. and Sue Chen Professor of Pediatrics, Division Chief, Medical Genetics, Duke University Medical Center
  • Chiyomi Kubo, PhD, DVM, Scientist, Research Division, Chugai Pharmaceutical Co., Ltd.
  • Kun Lu, PhD, Staff Scientist, Protein Biochemistry Group, Regeneron Pharmaceuticals, Inc.
  • Theo Rispens, PhD, PI Antibody Structure and Function, Sanquin
  • Amy S. Rosenberg, MD, Division Director, Office of Biotechnology Products, FDA/CDER
  • Jennifer Sims, Non-Clinical Expert, NDA Advisory Board, NDA Group
  • Karen Thudium, PhD, Head, Clinical Pharmacology Program, Cell and Gene Business Unit, Novartis

IMMUNOGENICITY ASSESSMENT AND REGULATORY APPROVAL OF BIOLOGICS

  • Tudor Arvinte, PhD, Professor, Biopharmaceutics, School of Pharmacy Geneva-Lausanne, University of Geneva and Therapeomic, Inc.
  • Bjorn Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Physical Chemical Analytics, Novartis Pharma AG
  • Steven Bowen, PhD, Immunogenicity Reviewer, OBP/OPQ/CDER, FDA
  • Shan Chung, PhD, Principal Scientist and Group Leader, Genentech, Inc.
  • Julio Delgado, MD, MS, CMO, ARUP Laboratories; Division Chief, Clinical Pathology, University of Utah School of Medicine; Associate Professor, Pathology, University of Utah
  • William Hallett, PhD, Product Quality & Immunogenicity Reviewer, CDER/OPQ/OBP, FDA
  • Marisa K. Joubert, PhD, Principal Scientist, Process Development, Amgen, Inc.
  • Lynn Kamen, PhD, Scientist, BioAnalytical Sciences, Genentech
  • Uma Kavita, PhD, Senior Research Investigator, Analytical and Bioanalytical Operations, Bristol-Myers Squibb
  • Bernard Maillere, PhD, Director, Research and Head of Immunochemistry Laboratory, Institute Frederic Joliot, SIMOPRO, CEA, University Paris-Saclay
  • Shraddha Rane, PhD, Postdoctoral Research Associate, Infection Immunity and Respiratory Diseases, The University of Manchester
  • Susan Richards, PhD, Presidential Scientific Fellow, Translational Medicine Early Development, Sanofi R&D
  • Theo Rispens, PhD, Immunopathology, Sanquin Research, Amsterdam, Netherlands
  • Zuben E. Sauna, PhD, Research Biologist & Principal Investigator, Haemostasis Branch, Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, FDA/CBER
  • Daniela Verthelyi, PhD, Chief, Laboratory of Immunology, Office of Biotechnology Products, Office of Pharmaceutical Quality, CDER
  • Zhandong Don Zhong, PhD, Associate Director, Teva Pharmaceuticals

OPTIMIZING BIOASSAYS FOR BIOLOGICS

  • Joseph Callahan, PhD, Technical Development Scientist, Genentech, Inc.
  • Shan Chung, PhD, Principal Scientist and Group Leader, Bioanalytical Sciences, Genenetech, Inc.
  • Gael Debauve, PhD, Associate Director, Bioassay Development, Analytical Sciences for Biologics, UCB
  • Jenny Hu, Scientist, PKDM, Amgen, Inc.
  • Natalia Kozhemyakina, PhD, Head, Bioassay Laboratory, Analytical Development Department, BIOCAD
  • Emily Lowe, PhD, Senior Scientist, Analytical Sciences, Kite Pharma, a Gilead Company
  • Areti Manola, Senior Principal Biostatistician, Non-Clinical Statistics, Manufacturing, Toxicology and Applied Statistical Sciences, Janssen, Pharmaceutical Companies of Johnson and Johnson
  • Kenneth R. Miller, PhD, Principal Scientist, Global Technical Operations, Analytical, AstraZeneca
  • Ashley Mullan, Scientist, Development, Analytical Sciences, MedImmune
  • Sandra Prior, PhD, Senior Scientist, Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
  • Perceval Sondag, Senior Manager, Statistics, PharmaLex
  • Dirk Usener, PhD, Head, Analytical Development 2, Bioanalytics, Sanofi
  • Steven Walfish, Principal Scientific Liaison, USP
  • Adrienne Wildt, PhD, Senior Scientist, Bioanalytical Science, Immunogen

Bioconjugates Stream
FUSION PROTEIN THERAPEUTICS

  • Ruben Boado, PhD, Vice President, Research & Discovery, ArmaGen Technologies, Inc.
  • Mathieu Cinier, PhD, CSO, Affilogic
  • Christina M. Coughlin, MD, PhD, CMO, Immunocore, LLC
  • Madiha Derouazi, PhD, CEO, Amal Therapeutics
  • Stephen D. Gillies, PhD, Founder & CEO, Provenance Biopharmaceuticals
  • Jeffrey Greve, PhD, Founder and CSO, Delinia, Inc. (Celgene)
  • Ravindra Kumar, PhD, Senior Vice President & CSO, Acceleron Pharma, Inc.
  • Ekkehard Moessner, PhD, Group Leader and Scientist, Protein Engineering, Roche Innovation Center Zurich
  • Nicola Pozzi, PhD, Assistant Professor, Biochemistry and Molecular Biology, Saint Louis University
  • Taylor Schreiber, MD, PhD, CSO and Co-Founder, Shattuck Labs, Inc.
  • Oliver Siefert, PhD, Scientist, Institute of Cell Biology and Immunology, University of Stuttgart
  • Patrik Stromberg, PhD, MBA, Senior Director, Head, Biomedical Science & Portfolio Innovation, Swedish Orphan Biovitrum AB (SOBI)
  • Li Tao, PhD, Research Fellow, Biologics Development, Bristol-Myers Squibb Company
  • Kenneth W. Walker, PhD, Director, Research, Therapeutic Discovery, Amgen, Inc.
  • Zhirui Wang, PhD, Assistant Professor, Surgery, Harvard Medical School; Senior Investigator/Head, Immunotoxin Laboratory, Center for Transplantation Sciences (CTS), Massachusetts General Hospital
  • Stefan Weigand, PhD, Global Head, Large Molecule Research, Roche Diagnostics GmbH
  • Sunny Zhou, PhD, Professor and Faculty Fellow, Chemistry and Barnett Institute, Northeastern University

ENGINEERING ANTIBODY-DRUG CONJUGATES

  • Roger Beerli, PhD, CSO, NBE-Therapeutics AG
  • Dennis Benjamin, PhD, Senior Vice President, Translational Research, Seattle Genetics
  • Ravi Chari, PhD, Vice President, Chemistry & Biochemistry, ImmunoGen, Inc.
  • Kurt Gehlsen, PhD, Vice President & CSO, Therapeutics, Research Corporation Technologies, Inc.
  • Yelena Kovtun, Associate Director, Pipeline R&D, ImmunoGen, Inc.
  • Chawita Netirojjanakul, PhD, Scientist, Therapeutic Discovery, Amgen
  • Andreas Pahl, PhD, CSO, Heidelberg Pharma
  • Obadiah J. Plante, PhD, Director, Research, Visterra, Inc.
  • Jan E. Schnitzer, MD, Director, Professor, Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
  • Ginette Serrero, PhD, CEO, A&G Pharmaceutical, Inc.
  • Philipp R. Spycher, PhD, PSI Founder Fellow, Center for Radiopharmaceutical Sciences, Paul Scherrer Institut
  • Breanna S. Vollmar, PhD, Senior Scientific Researcher, Protein Chemistry, Genentech, Inc.
  • Alain Wagner, PhD, Research Director, Biofunctional Chemistry, Faculty of Pharmacy, University of Strasbourg
  • Robert Yongxin Zhao, PhD, CEO, Hangzhou DAC Biotech Co., Ltd.

CLINICAL PROGRESS OF ANTIBODY-DRUG CONJUGATES

  • Adnan Abu-Yousif, PhD, Senior Scientist II, Discovery, Takeda
  • Donald A. Bergstrom, MD, PhD, CMO, Mersana Therapeutics
  • Anna Berkenblit, MD, MMSc, Vice President, CMO, ImmunoGen
  • Mahendra Deonarain, PhD, CEO & CSO, Antikor Biopharma Ltd.
  • David Goldenberg, ScD, MD, Founder and Former CSO, Immunomedics, Inc.
  • Trevor J. Hallam, PhD, CSO, Sutro Biopharma
  • Jay Harper, PhD, Senior Scientist, Oncology Research, MedImmune
  • Philip Howard, PhD, CSO, Spirogen; Senior Fellow, MedImmune
  • Gail Lewis Phillips, MSc, Senior Scientist, Translational Oncology, Genentech, Inc.
  • David (Shih-Yao) Lin, MD, PhD, CMO, AbGenomics, Inc.
  • Ed Reilly, PhD, Senior Research Fellow, Project Director, Oncology Discovery, AbbVie
  • Renu Singh Dhanikula, PhD, Senior Research Investigator, MAP, Bristol-Myers Squibb Company
  • Pamela Trail, Independent Consultant and Former Vice President, Oncology, Regeneron
  • Alessandra Micaela Villa, PhD, Head, Phage Display Technologies, Philochem AG
  • Jeff Wallin, PhD, Senior Director and Head, Biomarkers & Diagnostics, Seattle Genetics
  • William C. Zamboni, PharmD, PhD, Associate Professor and Director, Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Laboratory, UNC Lineberger Comprehensive Cancer Center

Therapeutics & Technologies Stream
EMERGING INDICATIONS FOR THERAPEUTIC ANTIBODIES

  • Dan Allison, PhD, Senior Director, Antibody Technologies, Alder Biopharmaceuticals
  • Robin Barbour, Head, Antibody and Assay Development, Research, Prothena Biosciences
  • Gabriela Dos Santos Cruz De Matos, PhD, Senior Scientific Investigator, Biopharm Molecular Discovery, GlaxoSmithKline, United Kingdom
  • Joachim Feldwisch, PhD, Director, Preclinical Development, Affibody AB, Sweden
  • Robert P. Giugliano, MD, Senior Investigator, TIMI Study Group, Staff Physician, Cardiovascular Medicine, Brigham and Women’s Hospital; Associate Professor, Medicine, Harvard Medical School
  • Gregory C. Ippolito, PhD, Research Assistant Professor, Molecular Biosciences, Georgiou Lab, The University of Texas at Austin
  • Leonard Kaczmarek, PhD, Professor, Pharmacology, Cellular and Molecular Physiology, Yale University School of Medicine
  • Hikaru Koga, Researcher, Biologics Discovery Department, Chugai Pharmaceutical Co., Ltd., Japan
  • Thomas Mikita, PhD, Director, Centers for Therapeutic Innovation, Pfizer, Inc.
  • Janice M. Reichert, PhD, Executive Director, The Antibody Society
  • Luke Robinson, PhD, Associate Director, Research, Visterra, Inc.
  • Dan Sexton, PhD, Director, Pharmacology, Shire
  • Devin Sok, PhD, Director, Antibody Discovery and Development, International AIDS Vaccine Initiative (IAVI)
  • Christine Tkaczyk, PhD, Senior Scientist, Infectious Diseases/Vaccines, MedImmune
  • Tianlei Ying, PhD, Head, Antibody Engineering and Drug Discovery Group, School of Basic Medical Science, Fudan University, China
  • Ali Zarrin, PhD, Senior Scientist, Immunology and Antibody Engineering, Genentech

CRISPR FOR GENOME ENGINEERING

  • Aaron T. Cheng, PhD, Head, PTS Discovery Genome Editing, Protein Cellular and Structural Sciences, R&D Platform Technology & Science, GlaxoSmithKline
  • Patrick Collins, PhD, Senior Scientist, Genome Analysis Unit, Amgen
  • Michael Dyson, PhD, CTO, Antibody Engineering, IONTAS, Ltd.
  • John Feder, PhD, Associate Director, Genome Biology, Bristol-Myers Squibb
  • Gus Frangou, PhD, Fellow, Molecular and Integrative Physiological Sciences, Harvard TH Chan School of Public Health
  • Judith Greengard, PhD, RAC, Director, Bioanalytics and Development, Sangamo Therapeutics
  • Tony Ho, MD, Executive Vice President, Head of R&D, CRISPR Therapeutics
  • Fuguo Jiang, PhD, Postdoc Fellow, Molecular and Cell Biology, University of California, Berkeley
  • Colin A. Johnson, PhD, Professor of Medical & Molecular Genetics, Section of Ophthalmology and Neurosciences, Leeds Institute of Molecular Medicine
  • Julia Joung, Graduate Student. Biological Engineering, MIT
  • Kristian Laursen, PhD, Professor, Pharmacology, Cornell University
  • Chengzu Long, PhD, Asst Professor, Department of Medicine, New York University
  • Bettie Osuna, PhD, Graduate Student, Bondy-Denomy Lab, University of California, San Francisco

NANOTECHNOLGY IN MEDICINE

  • Itai Benhar, PhD, Professor, Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel Aviv University
  • Michelle Bradbury, MD, PhD, Director, Intraoperative Imaging, Radiology, Memorial Sloan Kettering Cancer Center
  • Jose Luis Corchero Nieto, PhD, Senior Scientist, Nanobiotechnology Group, CIBER-BBN, Institute of Biotechnology and Biomedicine, Universitat Autonoma de Barcelona
  • Brian T. Cunningham, PhD, Willett Professor of Engineering, Director, Micro and Nanotech Lab, Electrical and Computer Engineering, University of Illinois at Urbana -Champaign
  • Daryl Drummond, PhD, Head of Research, Merrimack Pharmaceuticals
  • Ali Fattom, PhD, Senior Vice President, Vaccine R&D, NanoBio Corp.
  • Seungpyo Hong, PhD, Professor, Pharmaceutics, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison
  • Taeghwan Hyeon, PhD, SNU Distinguished Professor, School of Chemical and Biological Engineering, Seoul National University
  • Kei Kishimoto, PhD, CSO, Selecta Biosciences
  • Paul Millner, PhD, Professor of Bionanotechnology, School of Biomedical Sciences, University of Leeds
  • Hayat Onyuksel, PhD, Professor, Biopharmaceutical Sciences, University of Illinois
  • Jianghong Rao, PhD, Professor, Radiology and Chemistry (courtesy), Molecular Imaging Program, Cancer Biology and Biophysics Programs, Stanford University
  • Jan E. Schnitzer, MD, Director, Professor of Cellular & Molecular Biology, Proteogenomics Research Institute for Systems Medicine (PRISM)
  • Jinjun Shi, PhD, Assistant Professor, Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School
  • Matthias Stephan, MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington

TRAINING SEMINARS

  • David Bramhill, PhD, Founder, Bramhill Biological Consulting, LLC
  • Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
  • Masha Fridkis-Hareli, MSc, PhD, Founder and President, ATR, LLC
  • Simon Friedensohn, MSc, Research Assistant; Biosystems Science and Engineering, ETH Zurich, Switzerland
  • Arno Kromminga, PhD, Member, European Immunogenicity Platform, Senior Vice President and European CSO, BioAgilytix
  • Sheila G. Magil, PhD, Senior Consultant, BioProcess Technology Consultants, Inc.
  • Enkelejda Miho, Ph.D., Research Assistant II, Biosystems Science and Engineering; Pioneer Innovation & Entrepreneurship Lab, ETH Zurich, Switzerland
  • Tatiana Novobrantseva, PhD, Co-Founder, Head of Research and Development, Verseau Therapeutics
  • Frank J. Riske, PhD, Senior Consultant, BioProcess Technology Consultants, Inc.
  • Perceval Sondag, Senior Manager, Statistics, PharmaLex
  • Traian Sulea, PhD, Senior Research Officer, Human Health Therapeutics, National Research Council Canada

SHORT COURSE INSTRUCTORS

  • Tara Arvedson, PhD, Director, Oncology Research, Amgen
  • Glareh Azadi, PhD, Senior Scientist, Translational PKPD, Merck Research Laboratories
  • Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.
  • Christine P. Chan, PhD, Principal Scientist, Global Manufacturing Science & Technology, Sanofi
  • Kelly Doering, PhD., DMPK Business Manager, Pharmaceutical Business, Waters
  • Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School
  • Isabel Figueroa, PhD, Scientist, PTPK, Genentech, Inc.
  • Dennis Ford, Founder and CEO, Life Science Nation
  • Ben Hock, PhD, Director, Immunogenicity, BioMarin Pharmaceuticals
  • Darshana Jani, MS, Senior Manager, Pfizer, Inc.
  • Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
  • Veronica Juan, PhD, Principal Scientist, Protein Sciences, Merck Research Labs
  • Scott L. Klakamp, PhD, Vice President of Chemistry and Biochemistry, Bioptix
  • Seema Kumar, PhD, Associate Director, Quantitative Pharmacology & Drug Disposition (QPD), R&D Global Early Development (GED), EMD Serono, a business of Merck KGaA, Darmstadt, Germany
  • Christian Kunz, PhD., Associate Director, MorphoSys AG
  • Vinodh B. Kurella, PhD, Senior Scientist, Protein Engineering, Immuno-Oncology Division, Intrexon Corp.
  • Paul Rhyne, PhD., VP, Biological Development Services
  • Jonas Schaefer, PhD, Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich
  • Ravi Shankar Singh, PhD, Associate Director, Clinical Pharmacology, Pfizer
  • Mohammad Tabrizi, PhD, Director Biologics Discovery, Merck Research Laboratories Palo Alto
  • Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL); Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU)
Choose your language
Chinese
Japanese
Korean
English

Premier Sponsors

Genedata

GenScript CRO Logo

Harbour Biomed

 LONZA tagline

Nanotemper Technologies

Pall Life Sciences

Precision for Medicine 

Schrodinger 

赞助商

媒体合作夥伴